Alerta

INFLUENZA VACCINE

Resumen de: US20260216315A1

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Nanostructure Enhanced Targeting (NSET) of Inflammatory Cells

Resumen de: US20260216076A1

The present invention provides nanomaterials for the specific targeting of immune cells. Methods of treating cardiac disease and inflammatory disease are also described.

NANOPARTICLES ENCAPSULATING SOLUBLE BIOLOGICS, THERAPEUTICS, AND IMAGING AGENTS

Resumen de: US20260216090A1

0000 An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.

ANALGESIC COMPOSITIONS, METHOD OF MANUFACTURE AND USES THEREOF

Resumen de: US20260216214A1

Disclosed herein is an analgesic composition comprising a therapeutically effective amount of at least one endocannabinoid, at least one cannabinoid, or a combination of the endocannabinoid and cannabinoid and at least one local anesthetic; where the 2024/130236 endocannabinoid comprises one or more endocannabinoids, one or more analogues of the endocannabinoids, one or more pharmaceutically acceptable salts of the endocannabinoid, or a combination thereof; where the cannabinoid comprises one or more cannabinoids, one or more analogues of the cannabinoids, one or more pharmaceutically acceptable salts of the cannabinoid, or a combination thereof; where at least one of the endocannabinoid or the cannabinoid is in the form of particles.

COMPOUND, NANOPARTICLES, MEDICINE, AND METHOD FOR PRODUCING NANOPARTICLES

Resumen de: US20260216346A1

0000 A compound represented by General Formula (1) or a salt thereof, in which each of R<1 >and R<2 >independently represents an alkyl group having 1 to 4 carbon atoms, R<1 >and R<2 >may be bonded to each other to form a ring together with a carbon atom to which R<1 >and R<2 >are bonded, and each R<3 >independently represents an alkylene group having 1 to 4 carbon atoms; nanoparticles containing the compound or a salt thereof; a medicine containing the compound or a salt thereof; and a method for producing nanoparticles, including a step of injecting a water-miscible organic solvent solution of the compound or a salt thereof into water are provided. 0000

NANOBODY-DRUG CONJUGATES AND METHODS OF PREPARING THEREOF

Resumen de: US20260216361A1

0000 Disclosed herein are nanobody-drug conjugates that can effectively deliver drugs, such as STING agonists. An example conjugate includes an albumin-binding nanobody, a drug, and a linker attaching the nanobody to the drug. Also disclosed are methods of making and using the conjugates.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID-BASED THERAPEUTICS AND METHODS THEREOF

Resumen de: US20260216070A1

0000 The present disclosure provides compounds according to Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV used as a component of lipid nanoparticle compositions for the delivery of a biological and/or therapeutic agent. The present disclosure also provides novel, stable lipid nanoparticle compositions comprising one or more biological and/or therapeutic agents, methods of making the lipid nanoparticle compositions, and methods of delivering the lipid nanoparticle composition.

NANOMATERIALS COMPRISING TRIOLS

Resumen de: US20260216083A1

0000 The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS

Resumen de: US20260216069A1

The present invention provides a liposome preparation containing a population of liposomes containing a CD1d ligand compound, wherein the average particle size of the population of liposomes is 90 to 110 nm and the polydispersity index of particle size distribution is 0.2 or less, and the polydispersity index of the particle size distribution is 0.2 or less. The present invention also provides the use of the liposome preparation in the prevention or treatment of graft-versus-host disease and organ transplant rejection.

ACETYLCYSTEINE-STABILIZED GOLD NANOCLUSTERS FOR ACUTE KIDNEY INJURY, AND PREPARATION METHOD AND APPLICATION THEREOF

Resumen de: US20260216112A1

0000 An acetylcysteine-stabilized gold nanoclusters for acute kidney injury, and a preparation method and an application thereof. The acetylcysteine-stabilized gold nanoclusters (Au NCs-NAC) includes gold nanoclusters and acetylcysteine bound to the surface of the gold nanoclusters. The Au NCs-NAC includes surface ligand acetylcysteine and gold nanoclusters protected by the surface ligand. The Au NCs-NAC has an ultra-small size, and can be effectively enriched in mice kidneys. By clearing a significant amount of reactive oxygen or nitrogen species within the renal tubules, the Au NCs-NAC alleviate and treat glycerol-induced acute kidney injury. Additionally, the Au NCs-NAC possess anti-inflammatory capabilities and exhibits superior therapeutic efficacy compared to acetylcysteine. Furthermore, the Au NCs-NAC demonstrate excellent biocompatibility and biosafety.

NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: US20260216091A1

The present developments provide methods and compositions for treating and/or preventing autoimmune diseases. In certain aspects, the present disclosure relates to the use of short peptides loaded inside of nanoparticle nanospheres, nanocapsules, or PEGylated nanoparticles. Additionally, peptide-metal nanoparticle drug conjugates are described and disclosed. In some embodiments, these nanoparticles, whether polymer based or metal-conjugated, when linked or coupled to bioactive peptides provided herein, may be capable of interacting with CD40 proteins or CD40 complexes, and thereby may interfere with the ability of CD40 to interact with CD154. The present disclosure also relates to the use of such nanoparticle-peptide conjugates in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present disclosure also relates to the use of such short peptides to prevent or reverse autoimmune disease, in particular in type 1 diabetes and multiple sclerosis, in individuals suffering from such diseases.

Circular RNA compositions and methods

Resumen de: AU2026205547A1

ACTIVE/103517556.9 Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches. ul u l

STEROL ANALOGS IN LIPID NANOPARTICLE FORMULATIONS

Resumen de: US20260216089A1

Provided are lipid nanoparticles for delivering nucleic acids molecules such as mRNA. Also provided are methods of making and using thereof.

NUCLEIC ACID DELIVERY COMPOSITIONS

Resumen de: US20260216371A1

0000 Compositions and methods for delivering nucleic acids (e.g., DNA) to cells are described herein. In some embodiments, such compositions and methods involve the use of lipid nanoparticles (LNPs).

NANOPARTICLE-NHE3 PEPTIDE TO TREAT DIARRHEA

Resumen de: US20260217768A1

Disclosed are NHE3 mimetic peptides and their conjugates with a reporter molecule or a carboxylated, branched poly(β-amino ester) (PBAE) nanoparticle and their use for treating diarrhea.

SPIRAL-STRUCTURED CHIP FOR PREPARING LIPID NANOPARTICLES, AND METHOD FOR PREPARING LIPID NANOPARTICLES BY USING SAME

Resumen de: US20260216092A1

0000 Embodiments relate to a chip for producing lipid nanoparticles including a spiral structure and a method for producing lipid nanoparticles using the same. According to one embodiment, it is possible to increase the efficiency of mixing between an aqueous-phase solution containing a nucleic acid and an oil-phase solution containing lipids, thereby forming uniform lipid nanoparticles by self-assembly at the interface between the aqueous-phase solution and the oil-phase solution. Moreover, one embodiment relates to a production method capable of efficiently producing lipid nanoparticles having a uniform shape and diameter using the chip for producing lipid nanoparticles including a spiral structure.

NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY

Resumen de: US20260216087A1

Novel ionizable lipid compounds, compositions comprising such ionizable lipid compounds, and related methods of their use are disclosed. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including biologically active agents, such as siRNA or mRNA, are useful in the delivery of said biologically active agents to subjects in need thereof.

INTERTUMORAL AND INTRATUMORAL DELIVERY OF CYTOKINES USING MESOPOROUS SILICA RODS AS AN IMMUNOMODULATING SYSTEM

Resumen de: US20260216086A1

Embodiments of the invention include methods of treating conditions that are ameliorated by stimulating an immune response. In aspects, the methods include injection of mesoporous silica rods (MSRs) at or near an affected tissue. The MSRs can include a cytokine (e.g., IL-2 or IL-12) and/or an adjuvant. The MSRs can induce an innate immune response to treat cancer, infection and other ailments. The methods can include administering an additional medicament such as an immune checkpoint inhibitor.

VACCINE COMPOSITION COMPRISING DOUBLE-STRANDED DNA-BOUND GOLD NANOPARTICLE CARRIER

Resumen de: US20260216316A1

0000 The present invention relates to a vaccine composition including double-stranded DNA delivered into cells via gold nanoparticles, and more particularly, to a vaccine composition characterized in that the double-stranded DNA is derived from a viral, bacterial or cancer gene and expresses an antigen to induce an immune response.

BILAYER MEMBRANE THAT PROMOTES BONE REGENERATION AND PREVENTS POST-OPERATIVE COMPLICATIONS

Resumen de: US20260216094A1

A bilayer membrane that promotes bone regeneration and prevents postoperative complications, is resorbable, and has an antibacterial effect, composed of: an outer layer; and an inner layer that is located in contact with the outer layer and in contact with the area to be treated, where the outer layer of the membrane comprises a polyhydroxybutyrate (PHB)-based polymer and silver nanoparticles (AgNP), and the inner layer of the membrane comprises polycaprolactone (PCL) loaded with calcitriol.

SELECTIVE INHIBITORS OF C. ACNES HYALURONIDASE

Resumen de: US20260217764A1

0000 Described herein are peptide inhibitors of C. acnes hyaluronidase. Also described are method of using these peptide inhibitors to treat acne.

CONJUGATE AND USES THEREOF

Resumen de: US20260216366A1

A conjugate comprises: (a) a single-domain antibody (sdAb) that specifically binds to a tumor antigen, (b) a drug, and (c) a functional linker which links the drug to the sdAb. The use of the conjugate is treating cancer. The method for preparing the conjugate comprises conjugating the functional linker and the drug to the sdAb.

STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF

Nº publicación: US20260217755A1 30/07/2026

Solicitante:

JENKEM TECH CO LTD LIAONING [CN]
CANSINO SHANGHAI BIOLOGICAL RES CO LTD [CN]
JENKEM TECHNOLOGY CO., LTD. (LIAONING)
CANSINO (SHANGHAI) BIOLOGICAL RESEARCH CO., LTD.

Resumen de: US20260217755A1

0000 A steroid-cationic lipid compound as represented by formula (I). The LNP prepared from the compound can deliver a bioactive substance to a target cell or organ in an effective and stable manner, and the mRNA LNP prepared from the compound has good levels of stability and transfection efficiency, and can trigger a relatively high specific antibody response and cellular immune response in an animal. 0000